Skip to content

Conjugated Estrogens

According to the PREMARIN label, PREMARIN is a mixture of estrogens indicated for treatment of moderate to severe vasomotor symptoms and vulvar and vaginal atrophy due to menopause, among its other approved uses. MedlinePlus describes estrogen as a hormone medicine that works by replacing estrogen the body is no longer producing at the same level. Conjubrook and Premarin both supply conjugated estrogens as a 0.625 mg tablet.

Conjubrook

Menopausal Vasomotor Symptoms, Vulvar Atrophy

0.625mg

Intended to relieve menopausal hot flashes to support comfort levels and target bone loss.

From$5.04/ tabletView

Premarin

Menopausal Vasomotor Symptoms

0.625mg

Indicated to address hormone depletion to relieve hot flashes and support structural bone mineral density.

From$5.04/ tabletView

Key points

  • The PREMARIN label describes its 0.625 mg tablet, the strength recorded for both attached products, as oval and maroon.
  • Premarin’s boxed warning names probable dementia as one of four risk areas: the Women’s Health Initiative Memory Study found an increased risk of developing probable dementia in postmenopausal women 65 years of age or older taking estrogen-alone therapy.
  • The label’s most common adverse reactions, each occurring in 5% or more of patients, include abdominal pain, headache, nausea, depression, breast pain and endometrial hyperplasia.

Boxed warning: four risk areas

Premarin’s FDA label opens with the heading “WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER and PROBABLE DEMENTIA.” The label states there is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. It also reports that the Women’s Health Initiative estrogen-alone substudy found increased risks of stroke and deep vein thrombosis in postmenopausal women during years of treatment with daily oral conjugated estrogens, relative to placebo, and that the estrogen plus progestin substudy demonstrated an increased risk of invasive breast cancer. The Women’s Health Initiative Memory Study found an increased risk of developing probable dementia in postmenopausal women 65 years of age or older; the label states it is unknown whether this finding applies to younger postmenopausal women.

Further reading